The discovery of new cancer therapeutics has seen a significant shift towards biologicals as an
alternative to small molecule drugs. Alternative binding peptide molecules, derived from
combinatorial scaffold libraries, are now challenging traditional antibodies. This report identifies the
competitive terrain for cancer therapeutic peptides to be wide open from a compound perspective
and the opportunity for peptide drugs to challenge other biologicals such as antibodies is real and
significant.
This report includes defined and up to date development strategies for 92 cancer therapeutic
peptide drugs (>170 projects) within the portfolio of 70 investigators, from Ceased to Marketed. In
total the report assesses 30 different cancer indications. The report is written for you to understand
and assess the impact of competitor entry and corresponding changes to development strategies for
your own portfolio products. It serves as an external commercial advocate for pharmaceutical
companies’ portfolio planning and new product planning by:
Providing you with competitive input to the R&D organization to guide development of early
product ideas and ensure efforts are aligned with business objectives
Assisting you to make informed decisions in selecting cancer indications that are known to
be appropriate for your drug's properties
Analyzing, correlating and integrating valuable data sources in order to provide accurate
data for valuation of pipeline, in-licensing and new business opportunities
Providing you with commercial analytic support for due diligence on in-licensing and
acquisition opportunities
Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment
This report will also be an important part of creating and implementing a market development plan
for any cancer therapeutic peptide drugs to ensure that the optimal market conditions exist by the
time the product is commercialized.
(0 items)
